10 July 2026
Aspen Chair Transition will see Ben Kruger replace Kuseni Dlamini as Aspen Pharmacare prepares for debt-free growth and new investment.
16 March 2026
Learn about potential Aspen Pharmacare asset disposals aimed at optimising the company's global operations for greater profitability.
7 March 2026
Aspen Pharmacare Debt-Free marks a pivotal moment in its history as it shifts focus toward GLP-1 injectables like semaglutide.
7 November 2025
Aspen Pharmacare resolves its mRNA dispute with a R500m settlement, stabilising its earnings and share price significantly.
5 November 2025
Aspen's Mounjaro expansion plans promise to enhance diabetes and weight management treatment in Sub-Saharan Africa soon.
4 September 2025
Understand Aspen Unlocking Value efforts as CEO Stephen Saad addresses the decline in share price and targets business improvements.
30 October 2024
Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.